Dapagliflozin Performance In Phase III Leaves Concerns,Particularly About Urinary Infections

Phase III results for Bristol-Myers Squibb/AstraZeneca’s dapagliflozin released at the 2010 American Diabetes Association meeting are raising questions about whether the SGLT-2 inhibitor and others like it have a chance at competing for a second-line role against DPP-4 inhibitors, despite worrisome urinary infection side effects.